Public-registry trials using XNW5004 800 mg or 1200 mg (1:1 randomization) that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| Study of XNW5004 Tablets in Advanced Prostate Cancer | Evopoint Biosciences Inc. | Advanced Prostate Cancer | PHASE2 | 0 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →